Translating Metastasis Research into New Models and Therapies

 

1% of cancer research papers focus on metastatic cancer Less than 5% of cancer funding goes towards tackling metastatic cancer The clinical success rate of cancer drugs has dropped to 3.4% 90% of cancer deaths are caused by metastasis

Understanding and tackling metastatic cancer is the single biggest opportunity to improve outcomes for the most cancer patients.

But it also represents a huge opportunity to (1) improve the development of existing cancer drugs, (2) reverse declining clinical success rates in oncology, (3) drive the development of new therapies, (4) treat more aggressive cancers and improve survival rates for metastatic cancers and (5) to develop new preclinical models and testing approaches.

This multi-disciplinary summit is for cancer/metastasis researchers, drug developers, clinicians, patient organisations and technology companies. The wide-spectrum of attendee backgrounds is a core strength of this meeting, which is one for the entire oncology community. Unlike other (excellent) metastasis meetings, the focus of this summit is translational.

We will explore and discuss:

  • The development and use of new, clinically-relevant models of metastasis to support experimental therapeutic studies and research, and reveal new insights that are not apparent when undertaking standard preclinical studies. .

  • New therapeutic opportunities for (1) specifically targeting metastatic disease, and (2) to support the performance/development of existing cancer drugs.

  • The translation of a fast-growing wealth of metastasis research into new cancer therapeutics. Where are the next giant-leaps likely to be made?

  • How advances in CAR-T and other immunotherapies is impacting our understanding of advanced cancer and metastasis.

  • AI and other data-driven approaches to support anti-metastatic therapy development.

  • The discovery of new targets relating to metastasis, and the most likely candidate targets for impressive future breakthroughs.

  • The role of metastasis research in reversing the declining rate of oncology clinical trial success.

  • Alternative approaches to tackling metastatic cancer, such as cancer metabolism and the emerging influence of the microbiome.

  • The development of new early diagnostic technologies relating to metastasis.

Speakers: We have had an incredible amount of support from the oncology community in putting this event together. As a result, the speaker line-up is unrivalled in terms of it’s breadth and depth of experience and ideas, including world-renowned cancer researchers, global pharma companies, emerging biotechs, tech companies and innovative, young researchers.

Pricing and Access: This is a socially-motivated event, and prices to register are much lower than for a typical conference enabling the oncology community to access this event is the priority, over profit.

Vendors: There is no better place to showcase your metastasis-related product or service than at a focused, multi-disciplinary meeting like this. Sponsorship also subsidises low ticket prices, so in doing so you are also supporting the event and the oncology community overall. Contact Richard Lumb for more details on sponsorship/exhibition opportunities.

Thank you. So many people/organisations from the oncology community have supported the production of this event. We wanted to take this opportunity to say thank you!

Confirmed Speakers

J Carl Barrett.png

J. Carl Barrett
Global Lead Translational Medicine Oncology R&D
AstraZeneca

Bruce Zetter.png

Bruce Zetter
Professor of Cancer Biology
Harvard University

Bob Weinberg.png

Bob Weinberg
Daniel K. Ludwig Professor for Cancer Research
MIT

Bob Kerbel.png

Robert Kerbel
Senior Scientist, Biological Sciences, Odette Cancer Research Program
Sunnybrook Research Institute

Maria A.S Broggi
Exploratory Immuno-Oncology Investigator
Novartis Institutes for BioMedical Research

Shou-Ching Jaminet.png

Shou-Ching Jaminet
Founder and Head of Research
Angiex Inc.

Christopher Kloss
Scientist, CAR T Discovery and Platform Development
The Janssen Pharmaceutical Companies of Johnson & Johnson

Farshad Guirakhoo.png

Farshad Guirakhoo
Chief Scientific Officer
GeoVax, Inc.

Bruce Littlefield.png

Bruce Littlefield
Distinguished Scientist and Head, Translational Medicine
Eisai

Thomas Seyfried.png

Thomas Seyfried
Professor
Boston College

Andrew P Mazar.png

Andrew P Mazar
Chief Scientific Officer
Monopar Therapeutics

Kin-Hoe Chow
Associate Director, Center for Patient Derived Models
Dana-Farber Cancer Institute

Why Attend?

Lightbulb.png

Unlock New Therapeutic Avenues

Explore new targets, mechanisms and modalities.

Speakers.png

Shape Your Research Using Experts

Learn from the world’s leading cancer researchers.

Analysis.png

Improve Clinical Success

Optimize metastatic model use, discover new endpoints and trial paradigms.

Networking.png

Make New Connections

Network with experts from academia, healthcare and pharma.

Key Topics Include

Topic Banner 2.png
  • Translate metastasis research into the clinic. Understand which targets, mechanisms and therapeutic avenues hold the most promise.

  • Implement metastatic models. Uncover clinically-relevant findings from new and emerging models of metastatic disease, and improve modelling to tackle immune-oncology toxicity.

  • Stop metastasis earlier. Learn how and why, coupled with new methods to detect cancer, the potential to stop metastasis before it’s too later is increasing.

  • AI and metastasis. What if AI could help rethink the metastasis/resistance equation? Find out how.

  • Biomarkers and metastasis. Explore new methods to select drug candidates, new biomarkers for metastasis and which biomarkers are most likely to be meaningful for patients.

  • Dormancy. Discover the most therapeutically relevant advances in our understanding of dormancy in metastasis.

Topic Banner 1.png
  • Immuno-oncology and metastasis. As metastasis research and CAR-T therapies converge, understand how new CAR-T cells are being generated for the eradication of advanced cancers.

  • Cancer as a metabolic disease. Learn about the prospects for metabolic therapies, including the most likely targets and pathways.

  • Overcoming anti-metastatic bottlenecks. Discuss how to overcome the barriers and bottlenecks to drive the development of therapies that tackle metastasis.

  • The microbiome and metastasis. Uncover the impact of microorganisms in carcinogenesis, cancer progression and metastasis, and the therapeutic implications of recent findings.

  • Endpoints and clinical trials. Define the relationship between established and novel tumor-based endpoints with overall survival rates in patients treated with immunotherapy, and discover/discuss new trial paradigms and endpoints.

  • Leverage data-driven approaches. Streamline big data research into clinically actionable interventions for the treatment of metastatic disease.